April 29th 2024
Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Rosacea and gastro disorders possibly related
February 8th 2017Because rosacea is an inflammatory disease there is scientific rationale for a possible association between it and other inflammatory diseases. A recent study demonstrates that rosacea patients have a greater percentage of gastrointestinal disorders than do controls and should be evaluated further if they present with GI symptoms. In such cases a systematic approach to the treatment of both conditions may be warranted.
Updated guidelines for diagnosis, treatment of rosacea
January 31st 2017A revised and updated set of criteria and treatment recommendations establishes a phenotype approach to diagnosing and classifying rosacea. This approach marks a transition from treating rosacea patients according to subtype. Global representation may identify research needed to determine whether rosacea is a global condition.
More evidence of rosacea, autoimmune link
April 7th 2016While a cause-and-effect link is elusive, it’s possible that environmental and lifestyle factors could explain why rosacea patients appear to suffer more from various conditions. But recent genetic research has hinted at inherited links between rosacea and autoimmune disorders. Recent findings provide more evidence.
Facial erythema influences perceptions
November 12th 2015A recent study shows people with facial erythema were strongly associated with having poor health and negative personality traits. Participants reported negative impacts of rosacea emotionally, socially, and at work. Doctors should seek to address both the aesthetic as well as the psychological impacts of the disease.
Rosacea: Newer topical therapies are effective and well-tolerated
March 16th 2015Emerging therapies for rosacea have a favorable side effect profile and address specific symptoms of the condition; brimonidine, for example, addresses background erythema while ivermectin addresses the papules and pustules.
FDA Approves Ivermectin 1% Cream for Rosacea
January 2nd 2015Lead author and a Galderma consultant dermatologist Linda Stein Gold, M.D. writes to Dermatology Times that results from Soolantra (ivermectin) Cream, 1% were seen in clinical studies as early as week two, with continuous improvement in patients with inflammatory lesions of rosacea.
Topical ivermectin emerges as option for rosacea
March 23rd 2014In the search for rosacea treatments, topical ivermectin 1 percent cream met its safety endpoints in two pivotal trials that included a total of 910 actively treated subjects, Galderma announced at the 72nd Annual Meeting of the American Academy of Dermatology.
Research sheds light on pathophysiology of acne, rosacea
November 1st 2013Although the symptoms of acne and rosacea are well established, clear and definitive etiologies of these conditions have largely been unknown. Recent research, however, has shed new light into the pathophysiology of these conditions, paving the way for more targeted therapies.